Atai Beckley NV
9VC
Company Profile
Business description
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
Contact
Prof. J.H. Bavincklaan
Amstelveen1183 AT
NLDT: +31 207932536
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.30 | 4.70 | 0.05% |
| CAC 40 | 8,143.47 | 7.17 | -0.09% |
| DAX 40 | 24,198.66 | 0.84 | -0.00% |
| Dow JONES (US) | 47,951.85 | 65.88 | 0.14% |
| FTSE 100 | 9,840.74 | 2.97 | 0.03% |
| HKSE | 25,690.53 | 192.40 | 0.75% |
| NASDAQ | 23,006.36 | 313.04 | 1.38% |
| Nikkei 225 | 49,507.21 | 505.71 | 1.03% |
| NZX 50 Index | 13,333.40 | 76.63 | 0.58% |
| S&P 500 | 6,774.76 | 53.33 | 0.79% |
| S&P/ASX 200 | 8,621.40 | 0.10 | -0.00% |
| SSE Composite Index | 3,890.45 | 14.08 | 0.36% |